Breakingviews - COMMENTARY: Novo Nordisk’s obesity feast lacks a second course ↧ ↧ Breakingviews - COMMENTARY: Novo Nordisk’s obesity feast lacks a ... The $174 bln weight loss pioneer plans to expand in new treatments. Yet a promised extra $23 bln of revenue by 2035 will barely offset the loss of sales as its core Wegovy franchise comes off patent. And regaining ground will be hard in an obesity market fat with new competition.
published
Breakingviews - COMMENTARY: Novo Nordisk’s obesity feast lacks a second course ↧
Open the original public source →
Latest documented BWB result
$AMZN market result
Exit $AMZN Lotto for 50% profit
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.